Phase I clinical trials have been reported and, in 2020, a 118-patient study was reported demonstrating the effectiveness of [68Ga][Ga(THP-PSMA)] in influencing clinical management of prostate cancer before therapy by identifying metastases in bone [159]. Here, FOLH1 is linked to prostate carcinoma.